logo-loader
viewOncimmune

Oncimmune signs exclusive distribution deal in US for its lung cancer test

Adam Hill, chief executive of diagnostics group Oncimmune PLC (LON:ONC), details their exclusive distribution agreement in the US for its early stage lung cancer test.

The deal with Biodesix is worth US$28mln over five years and will also see the two companies work together to develop further the EarlyCDT test in both the US and elsewhere.

Quick facts: Oncimmune

Price: 37.5 GBX

AIM:ONC
Market: AIM
Market Cap: £23.72 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

New US deal for Oncimmune on the back of mixed results

Oncimmune Holdings PLC (LON:ONC) has inked a new deal with US diagnostics firm Biodesix for its EarlyCDT lung cancer test. CEO Adam Hill tells Proactive London how significant the deal is and lays out his new three year strategic vision for the company, underlining a newly-implemented and...

on 1/11/19

2 min read